Ranbaxy Laboratories Ltd., of Mumbai, India, said it received FDA approval to manufacture and market Fenofibrate capsules USP, 43 mg and 130 mg indicated for primary hypercholesterolemia, mixed dyslipidemia and severe hypertriglyceridemia. The FDA's Office of Generic Drugs has determined the formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Antara capsules, 43 and 130 mg, respectively, of Lupin Atlantis.